Fig 4.
Survival after recurrence for patients relapsing (A) within the first 18 months after study entry and (B) relapsing 18 months after study entry. HR, hazard ratio; mFF6, modified fluorouracil, leucovorin, and oxaliplatin for 6 months; mFF6 + Bev, mFF6 for 6 months plus bevacizumab for 12 months.